A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma Interventions: Biological: Nivolumab; Biological: Ipilimumab Sponsor: Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Research | Study | Yervoy